Effect of ShanZha, a Chinese herbal product, on obesity and dyslipidemia in hamsters receiving high-fat diet

被引:62
作者
Kuo, Daih-Huang [1 ]
Yeh, Ching-Hua [2 ,5 ]
Shieh, Po-Chuen [1 ]
Cheng, Kai-Chun [3 ]
Chen, Fu-An [1 ]
Cheng, Juei-Tang [3 ,4 ,5 ]
机构
[1] Tajen Univ, Dept Pharm, Yen Pou 90701, Ping Tung Shien, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan
[4] Chi Mei Med Ctr, Dept Med Res, Yung Kang 73101, Tainan Shen, Taiwan
[5] Chang Jung Christian Univ, Coll Hlth Sci, Inst Med Sci, Tainan 71101, Taiwan
关键词
ShanZha (Crataegus pinnatifida); Rosaceae; Obesity; Dyslipidemia; PPAR alpha; ACTIVATED-RECEPTOR-ALPHA; METABOLIC SYNDROME; LIPID-METABOLISM; 3T3-L1; CELLS; INHIBITS ADIPOGENESIS; CRATAEGUS-OXYACANTHA; ADIPOSE-TISSUE; MEDICINE; RATS; APOPTOSIS;
D O I
10.1016/j.jep.2009.05.005
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Aim: The present study is designed to investigate the effect of ShanZha (Crataegus pinnatifida) on obesity or dyslipidemia induced by high-fat diet in hamsters and characterize the role of PPAR alpha in this action of ShanZha. Materials and methods: We induced dyslipidemia and obesity in hamsters using high-fat diet and treated hamsters with ShanZha or vehicle for 7 days. We measured the body weight, adipose tissue weights, and food intake of hamsters. Plasma total cholesterol (TC), triglyceride (TG), LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) were determined at the beginning and end of this treatment. Effect of ShanZha on adipogenesis was examined in vitro and change of PPAR alpha was analyzed using Western blot. Results: The food intake, body weights, and weights of both brown and white adipose tissues were markedly reduced in hamsters receiving ShanZha as compared with the vehicle-treated control. Plasma levels of TC, TG and LDL-C were decreased by this ShanZha treatment while HDL-C was elevated. The effects of ShanZha were reversed by the combined treatment with PPAR alpha antagonist, MK886. ShanZha inhibited the fat droplet accumulation in 3T3-L1 adipocytes in a dose-dependent manner and this effect was abolished by MK886. Western blot results showed activation of PPAR alpha by ShanZha in hamster adipose tissue. Conclusion: We suggest that ShanZha could activate PPAR alpha to improve dyslipidemia or obesity. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:544 / 550
页数:7
相关论文
共 39 条
[1]  
Ahmed SM, 1998, AM FAM PHYSICIAN, V57, P2192
[2]   CELLULAR AND MOLECULAR ASPECTS OF ADIPOSE-TISSUE DEVELOPMENT [J].
AILHAUD, G ;
GRIMALDI, P ;
NEGREL, R .
ANNUAL REVIEW OF NUTRITION, 1992, 12 :207-233
[3]   Ligand-induced expression of peroxisome proliferator-activated receptor α and activation of fatty acid oxidation enzymes in fatty liver [J].
Akbiyik, F ;
Cinar, K ;
Demirpence, E ;
Ozsullu, T ;
Tunca, R ;
Haziroglu, R ;
Yurdaydin, C ;
Uzunalimoglu, O ;
Bozkaya, H .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (06) :429-435
[4]   The relationship between alkaline phosphatase activity and intracellular lipid accumulation in murine 3T3-L1 cells and human preadipocytes [J].
Ali, Aus T. ;
Penny, Clem B. ;
Paiker, Janice E. ;
Psaras, George ;
Ikram, Faisel ;
Crowther, Nigel J. .
ANALYTICAL BIOCHEMISTRY, 2006, 354 (02) :247-254
[5]  
AlMakdessi S, 1996, ARZNEIMITTELFORSCH, V46, P25
[6]   CRATAEGUS, TOXICOLOGY AND PHARMACOLOGY .1. TOXICITY [J].
AMMON, HPT ;
HANDEL, M .
PLANTA MEDICA, 1981, 43 (02) :105-120
[7]   PPARs: therapeutic targets for metabolic disease [J].
Berger, JP ;
Akiyama, TE ;
Meinke, PT .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :244-251
[8]   Peroxisome proliferator-activated receptor (PPAR)-α agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats:: A comparison with PPARγ agonism [J].
Bergeron, Raynald ;
Yao, Jun ;
Woods, John W. ;
Zycband, Emanuel I. ;
Liu, Cherrie ;
Li, Zhihua ;
Adams, Alan ;
Berger, Joel P. ;
Zhang, Bei B. ;
Moller, David E. ;
Doebber, Thomas W. .
ENDOCRINOLOGY, 2006, 147 (09) :4252-4262
[9]   Epidemiology, trends, and morbidities of obesity and the metabolic syndrome [J].
Bray, GA ;
Bellanger, T .
ENDOCRINE, 2006, 29 (01) :109-117
[10]   Systematic review on the risk and benefit of different cholesterol-lowering interventions [J].
Bucher, HC ;
Griffith, LE ;
Guyatt, GH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) :187-195